Multiple Sclerosis, 1 December 2003, vol. 9, no. 6, pp. 574-578(5)
Suzumura A.; Ito A.; Mizuno T.
 Department of Neuroimmunology, Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa, Nagoya 464-8601, Japan
The effects of phosphodiesterase inhibitors (PDEIs) on interleukin (IL)-12 production by microglia, antigen-presenting cells in the central nervous system (CNS), were examined to learn how they affect T cell differentiation in the CNS.
PDEIs significantly suppressed the microglial IL-12 production, as determined by reverse transcriptase-polymerase chain reaction for IL-12 p35 and p40 mRNA expression and by an ELISA specific for IL-12 functional heterodimer, p70.
In addition, the PDEI ibudilast also suppressed interferon-g, but not IL-4 or IL-10, production by myelin oligodendrocyte glycoprotein (MOG)-specific T cells reactivated with MOG in the presence of microglia.
Thus, PDEIs may also suppress differentiation of T helper 1 (Th1) in the CNS.
PDEIs can be of use for future therapeutic strategy to treat Th1-mediated diseases, such as multiple sclerosis.